NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JAPIC ID: JapicCTI-121964

Registered date:

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedpsoriasis
Date of first enrollment
Target sample size
Countries of recruitment
Study typeINTERVENTIONAL
Intervention(s)Intervention name : Secukinumab INN of the intervention : Secukinumab Dosage And administration of the intervention : subcutaneous injection Control intervention name : null

Outcome(s)

Primary OutcomeAE
Secondary OutcomePASI 75, IGA

Key inclusion & exclusion criteria

Age minimum18
Age maximum
GenderBOTH
Include criteria-Subjects who complete the full study treatment period of preceding phase III studies. -Subjects expected to benefit from participation in the extension study, as assessed by the subject and investigator Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both
Exclude criteria-Ongoing use of prohibited psoriasis or non-psoriasis treatments. -Other protocol-defined inclusion/exclusion criteria may apply.

Related Information

Contact

public contact
Name Novartis Pharma K.K. Novartis Direct
Address 0120-003-293
Telephone
E-mail
Affiliation
scientific contact
Name
Address
Telephone
E-mail
Affiliation